BACKGROUND: The histologic diagnosis of @entity1373 ( @entity1373 ) has been reported as having a high rate of @entity5 , either @entity3821 ( @entity3821 ) or @entity513 ( @entity513 ). We reviewed our surgical group's experience with @entity12740 ( @entity12740 ), specifically looking at the follow-up of @entity1373 . METHODS: From November 1994 through July 1997 our group performed 539 @entity12740 . Twenty-one @entity1 (4%) were diagnosed as @entity1373 . Eighteen @entity1 had subsequent wire-localized excisional biopsies. Three @entity1 were followed up mammographically. One @entity1 refused follow-up. RESULTS: Of the 18 @entity1 who underwent excisional biopsies, 2 @entity1 were found to have @entity3821 and 1 @entity1 had @entity1137 in-situ. There were no cases of @entity513 . CONCLUSION: Our results show a much lower incidence of @entity5 in cases of @entity1373 found on @entity12740 than has been previously reported. While the standard of care is still to follow up @entity1373 found on @entity12740 with excisional biopsy, more data may justify following up certain subsets of @entity1 .

Accuracy of stereotactic core-needle breast biopsy in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1137 :: ('MESH:D018275', 'Disease') :: ['lobular carcinoma'] @entity3821 :: ('MESH:D002285', 'Disease') :: ['ductal carcinoma in situ', 'DCIS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy'] @entity1373 :: ('MESH:D006965', 'Disease') :: ['ADH', 'atypical ductal hyperplasia'] @entity513 :: ('MESH:D044584', 'Disease') :: ['IDC', 'invasive ductal carcinoma'] @entity12740 :: ('MESH:D020512', 'Disease') :: ['SCNB', 'stereotactic core-needle biopsies']
@entity1373 :: (MESH:D006965,Disease) :: ['atypical ductal hyperplasia']
